Genocea Biosciences Inc (OTCPK:GNCAQ)
$ 0.0001 0 (0%) Market Cap: - Enterprise Value: - PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Genocea Biosciences Inc at Needham Healthcare Conference Transcript

Apr 12, 2022 / 06:15PM GMT
Release Date Price: $0.49 (-18.33%)
Gil Blum
Needham & Company, LLC - Analyst

Good afternoon, and welcome to day 2 of the Annual Needham & Company Healthcare Conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors.

It is my pleasure to have with me today Chip Clark, the CEO of Genocea. (Conference Instructions) And with that, Chip, you have the stage.

Chip Clark
Genocea Biosciences, Inc. - President & CEO

Thanks, Gil, and thank you to Needham for the opportunity to represent my colleagues back here in Cambridge, Massachusetts at Genocea where we will talk today about our work to develop next-generation neoantigen-targeted cancer immunotherapies. I will be making forward-looking statements today and so please be mindful of that fact.

Here is our story in a nutshell. We believe that our products are differentiated because they are designed that way. We have built the company around what we believe to be a differentiated neoantigen discovery platform that we call ATLAS.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot